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Genomic analysis is essential for risk stratification in patients with acute myeloid
leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing
is a potential replacement for conventional cytogenetic and sequencing approaches,
but its accuracy, feasibility, and clinical utility have not been demonstrated.
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METHODS

We used a streamlined whole-genome sequencing approach to obtain genomic
profiles for 263 patients with myeloid cancers, including 235 patients who had
undergone successful cytogenetic analysis. We adapted sample preparation, sequencing, and analysis to detect mutations for risk stratification using existing European Leukemia Network (ELN) guidelines and to minimize turnaround time. We
analyzed the performance of whole-genome sequencing by comparing our results
with findings from cytogenetic analysis and targeted sequencing.
Whole-genome sequencing detected all 40 recurrent translocations and 91 copynumber alterations that had been identified by cytogenetic analysis. In addition,
we identified new clinically reportable genomic events in 40 of 235 patients
(17.0%). Prospective sequencing of samples obtained from 117 consecutive patients
was performed in a median of 5 days and provided new genetic information in 29
patients (24.8%), which changed the risk category for 19 patients (16.2%). Standard AML risk groups, as defined by sequencing results instead of cytogenetic
analysis, correlated with clinical outcomes. Whole-genome sequencing was also
used to stratify patients who had inconclusive results by cytogenetic analysis into
risk groups in which clinical outcomes were measurably different.
CONCLUSIONS

In our study, we found that whole-genome sequencing provided rapid and accurate
genomic profiling in patients with AML or MDS. Such sequencing also provided a
greater diagnostic yield than conventional cytogenetic analysis and more efficient
risk stratification on the basis of standard risk categories. (Funded by the Siteman
Cancer Research Fund and others.)
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G

enetic profiling is a routine component of the diagnostic workup for an
increasing number of cancers and is used
to predict clinical outcomes and responses to
targeted therapies. Mutations that are clinically
actionable for any individual type of cancer typically span a wide range of genomic events, including chromosomal rearrangements, gene amplifications and deletions, and single-nucleotide
changes. The diversity of these findings necessitates the use of multiple platforms to obtain the
genetic information needed for clinical management. Whole-genome sequencing is an unbiased
method of detecting all types of mutations1 and
could potentially be used to replace current testing algorithms. Such sequencing can also be
performed on a limited amount of DNA and can
identify genomic changes that may be cryptic
in other types of analyses.2 These features of
whole-genome sequencing suggest that it could
improve genomic profiling in patients with
cancer.
Genomic abnormalities are particularly important for diagnostic classification and risk assessment in patients with acute myeloid leukemia
(AML) and myelodysplastic syndromes (MDS).
Recurrent chromosomal abnormalities are the
basis for the AML genomic classification system
of the World Health Organization, and the association of these alterations and certain genetic
mutations with clinical outcomes3-7 has led to
the development of algorithms for genetic risk
stratification in patients with AML.3,8 Similar
studies involving patients with MDS have resulted in the cytogenetic component of the International Prognostic Scoring System–Revised
(IPSS-R) in such patients.9 Although advances in
sequencing technology have improved the ability
to identify genetic mutations, the detection of
chromosomal rearrangements is primarily performed through conventional metaphase cytogenetic analysis (i.e., karyotyping). The latter approach is effective but has several limitations,
including the need to obtain viable cells, low
sensitivity, and limited resolution. Fluorescence
in situ hybridization (FISH) and targeted sequencing assays that use DNA, RNA, or both are also
used, but these methods are informative only in
the regions selected for analysis and may provide
incomplete information regarding identified
chromosomal rearrangements. As a result, conventional cytogenetic analysis remains an essenn engl j med 384;10

tial component of the diagnostic workup for
patients with AML or MDS.3,8
The importance of genetic profiling in such
patients and the variety of clinically relevant
mutation types suggest that whole-genome sequencing could be used in place of standard
testing approaches. Although the high cost of
sequencing and complex, time-consuming analysis methods have historically restricted such sequencing to research studies,10-16 recent advances
have made this analysis simpler to perform,
faster, and less expensive. In this study, we
developed a streamlined approach to wholegenome sequencing for genomic profiling of
patients with AML or MDS and applied it to diagnostic clinical samples in real time to evaluate
its feasibility, accuracy, and utility in the clinical
setting.

Me thods
Patients

This study was approved by the institutional review board at Washington University in St. Louis
and was conducted in accordance with the provisions of the Declaration of Helsinki. We obtained all the samples that were included in this
study from patients with a known or suspected
diagnosis of AML or MDS who were seen at the
Washington University School of Medicine. All
the patients provided written informed consent
for genomic sequencing studies. Retrospective
samples were obtained from cryopreserved diagnostic bone marrow or peripheral-blood specimens. Prospective samples were obtained from
fresh bone marrow aspirate or peripheral-blood
specimens collected from consecutive, unselected
patients for whom clinical cytogenetic analysis
by means of karyotyping had been requested
from May 2019 through February 2020.
Conventional Cytogenetic and Molecular
Analysis

All cytogenetic and FISH analyses were performed in the Cytogenomics and Molecular Pathology Laboratory at the Washington University
School of Medicine according to standard clinical protocols. We obtained data regarding genetic mutations as part of standard diagnostic
testing using polymerase-chain-reaction (PCR)–
based assays for the internal tandem duplication
mutation in FLT3 (FLT3-ITD) and the NPM1c muta-
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tion, a laboratory-developed clinical sequencing
assay, or both. (Details regarding the genetic
mutations is provided in the Supplementary Appendix, available with the full text of this article
at NEJM.org.) Cytogenetic and molecular results
were used to assign patients to established European Leukemia Network (ELN) or IPSS-R risk
categories.3,9
Genome Sequencing

We processed samples and performed sequencing to a target coverage depth of 60× in the Clinical Sequencing Laboratory at the McDonnell
Genome Institute of Washington University in
St. Louis, a laboratory that has been licensed
according to the Clinical Laboratory Improvement Amendments of 1988. This analysis involved
the identification of mutations in 40 genes,17
genomewide copy-number alterations greater than
5 Mbp, and structural variants matching 612
recurrent structural alterations in myeloid cancers. (Details regarding genetic identification
and structural variants are provided in Tables S1
and S2 in the Supplementary Appendix.) We used
the results of whole-genome sequencing to assign patients to a genetic risk group through the
same classification systems that are used for
conventional analyses.
Confirmatory Studies

We used FISH, PCR, chromosomal microarray
analyses, and RNA-sequencing data to confirm
findings on whole-genome sequencing that had
not been detected by cytogenetic analysis. We used
standard protocols to perform chromosomal
microarray analysis in the Washington University Cytogenetics Core. In the PCR-confirmation
analyses, we used primers designed to detect
structural variant breakpoints. The methods that
were used in RNA sequencing for structural variants have been reported previously.11
Statistical Analysis

In the time-to-event survival analysis involving
study patients with AML, we used death as the
end point for the Kaplan–Meier analysis or Cox
proportional-hazards regression to test for equal
survival across genetic risk groups. Additional
details regarding the methods that were used in
the statistical analysis are described in the Supplementary Appendix.
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R e sult s
Streamlined Approach to Whole-Genome
Sequencing

We developed a streamlined approach to wholegenome sequencing (ChromoSeq) that was designed to provide comprehensive genomic profiling of clinically relevant mutations in samples
obtained from patients with AML or MDS, while
minimizing the turnaround time and technical
complexity (Fig. 1A). In this approach, we used
scalable methods of sample preparation that can
be performed by a single technician in less than
8 hours with commercially available reagents,
followed by standard high-throughput sequencing. Automated tumor-only variant analysis detected mutations in selected genes, copy-number
alterations of more than 5 Mbp, and recurrent
structural variants18,19 (Tables S1 and S2). We
then summarized these findings in a concise
clinical report (Fig. S1A and S1B).
We performed a head-to-head comparison of
this approach with conventional cytogenetic analysis and targeted sequencing using 235 samples
obtained from patients with a known or suspected hematologic cancer who had undergone
successful cytogenetic analysis (Table 1, Fig. 1B,
and Table S3). This sequencing analysis yielded
a mean genome coverage of 50×; a mean of 5.1
clinically relevant mutations (range, 0 to 20)
were detected per patient across all variant types
(Fig. S1C and S1D). The sensitivity of wholegenome sequencing for recurrent translocations
that had been reported on cytogenetic analysis
was 100% (40 of 40 samples) (Fig. 2A).
Whole-genome sequencing identified cytogenetically cryptic structural variants in 13 patients,
including complex or cryptic chromosomal translocations involving the inv(16)(p13.1q22) fusion
gene CBFB–MYH11 in 2 patients, the t(7;21)
(p22;q22) fusion gene USP42–RUNX1 in 1 patient,
and 10 rearrangements involving KMT2A, all of
which were verified with the use of orthogonal
methods (Fig. 2B and Fig. S2A, Table S4, and
Section 1.5 in the Supplementary Appendix).
Whole-genome sequencing detected 100% (91 of
91) of the clonal copy-number alterations that
had been detected on cytogenetic analysis among
the 143 patients in whom conclusive and unambiguous results had been identified by karyotyping (Fig. 2A). In addition, sequencing identified
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263 Samples were obtained

117 Were prospective samples

146 Were retrospective samples

107 Were obtained from patients
with AML
87 Had successful cytogenetic
analysis
20 Had unsuccessful cytogenetic
analysis

39 Were obtained from patients
with MDS
39 Had successful cytogenetic
analysis

15 Underwent targeted sequencing

68 Were obtained from patients
with AML
64 Had successful cytogenetic
analysis
4 Had unsuccessful cytogenetic
analysis

42 Were obtained from patients
with MDS
38 Had successful cytogenetic
analysis
4 Had unsuccessful cytogenetic
analysis

62 Underwent targeted sequencing

35 Underwent targeted sequencing

7 Had other diagnosis
7 Had successful cytogenetic
analysis
7 Underwent targeted sequencing

Figure 1. Timeline of Whole-Genome Sequencing (WGS) Process and Study Design.
Panel A shows the workflow and approximate processing time for each step of the rapid WGS method used for samples obtained from
the study patients. As the first step in library construction, unfragmented DNA is cleaved and tagged for analysis in a process called tagmentation. Examples of the reports that were generated by this process are provided in Figures S1A and S1B in the Supplementary Appendix. Panel B shows the design of the study involving both retrospective and prospective cohorts of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The retrospective cohort included 146 samples obtained from individual patients
selected to represent a broad range of cytogenetic and molecular features of AML and MDS. The prospective cohort included 117 unselected, consecutive samples obtained from patients with a known or suspected myeloid cancer for whom cytogenetic testing was requested at the study center. Seven of these patients ultimately received a diagnosis other than AML or MDS. QC denotes quality control.
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Table 1. Characteristics of the Study Patients.*
Characteristic

Retrospective Cohort

Prospective Cohort

All study patients
No. of patients

146

117

No. of patients with successful cytogenetic analysis†

126

109

107

68

Patients with AML
No. of patients
Mean age — yr
Female sex — no. (%)

53.7

60.6

47 (44)

30 (44)

5

5

28

19

6

1

ELN genetic risk group — no. of patients‡
Acute promyelocytic leukemia with t(15;17)(q22;q21)/
PML–RARA
Favorable risk
t(8;21)(q22;q22.1)/RUNX1–RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB–MYH11
NPM1c without FLT3-ITD or with FLT3-ITDlow§
Biallelic CEBPA
Intermediate risk
t(9;11)(p21;q23)/KMT2A–MLLT3
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow§

11

2

8

15

3

1

22

10

1

1

11

6

NPM1c with FLT3-ITD or FLT3-ITDhigh§

7

3

Other risk not favorable or adverse

3

0

20

27

13

13

t(v;11q23.3)/KMT2A rearranged

3

0

inv(3)(q21.3q26.2) or t(3;3)(q21.3;26.2)/GATA2–MECOM

0

2

Chromosome 5 deletion, del(5q), or chromosome 7
deletion

2

3

Wild-type NPM1 with FLT3-ITD or FLT3-ITDhigh§

2

3

Adverse
Complex karyotype or mutated TP53

Mutated RUNX1 or ASXL1
Undetermined¶

0

6

32

7

39

42

Patients with MDS
No. of patients
Mean age — yr
Female sex — no. (%)

59.8

68.9

17 (44)

12 (29)

IPSS-R risk category — no. of patients‖
Very good

1

2

Good

11

17

Intermediate

10

3

4

5

13

6

0

9

Patients with other hematologic cancer**

NA

7

Acute lymphoblastic leukemia

NA

5

Poor
Very poor
Undetermined¶
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Table 1. (Continued.)
Characteristic
Other form

Retrospective Cohort

Prospective Cohort

NA

2

*	AML denotes acute myeloid leukemia, MDS myelodysplastic syndromes, and NA not applicable.
†	Successful cytogenetic analysis was defined as the analysis of at least three metaphase cells from cultures prepared
from tumor specimens with the use of conventional cytogenetic methods.
‡	Risk groups for patients with AML according to the European Leukemia Network (ELN) guidelines are listed by their
defining features and were assigned on the basis of results from conventional cytogenetic analysis; results from FISH
(performed at diagnosis) for PML–RARA, CBFB–MYH11, RUNX1–RUNX1T1, del(5q), and chromosome 7; results
from polymerase chain reaction (PCR) for FLT3-ITD; and results from targeted sequencing. At least 20 metaphase
cells were required to identify a normal karyotype. Nine patients with AML were assigned to a risk group on the basis of positive results on FISH for either PML–RARA (1 patient), CBFB–MYH11 (4 patients), or del(5q) (4 patients).
Three patients were classified as having intermediate risk on the basis of cytogenetic analysis and testing for NPM1c
and FLT3-ITD alone because targeted gene sequencing was not performed.
§	
FLT3-ITD status was obtained from clinical testing by means of PCR and capillary electrophoresis. High and low allele
ratios were determined on the basis of the established cutoff of 0.5 when available (in 7 of 30 patients with positive
results for FLT3-ITD); otherwise FLT3-ITD status was treated as a binary variable.
¶	The category of undetermined risk indicates that risk could not be classified because of inconclusive or unsuccessful
results on cytogenetic analysis (i.e., no metaphase cells were available for analysis or a normal karyotype was observed in <20 cells), as described previously.
‖	Risk categories are those used in the International Prognostic Scoring System–Revised (IPSS-R). The retrospective
cohort also included 2 patients with a t(6;9) translocation, which is risk-defining in AML but has no prognostic significance in MDS. Details are provided in Table S3 in the Supplementary Appendix.
**	Whole-genome sequencing was performed on samples obtained from consecutive patients, some of whom subsequently received a diagnosis other than AML or MDS, including acute lymphoblastic leukemia, paroxysmal nocturnal
hemoglobinuria, and no pathological diagnosis. Three of the patients with acute lymphoblastic leukemia had positive
results for BCR–ABL1, which was detected by whole-genome sequencing.

21 new copy-number alterations in 14 of these
patients, 12 of which were confirmed by other
methods (Fig. 2C, Table S5, and Fig. S2B). The
remaining 9 new copy-number alterations showed
altered coverage patterns on whole-genome sequencing but could not be confirmed by orthogonal methods because of their small size, low
abundance, or both (Fig. 2C, Fig. S2C, and Table
S5). Whole-genome sequencing also provided
definitive identification of copy-number alterations in an additional 13 patients with ambiguous or inconclusive results by cytogenetic analysis (Table S5). When we combined these results
with the findings in 14 patients who had conclusive results by cytogenetic analysis and newly
identified copy-number alterations, plus the findings in 13 patients who were identified as having new structural variants, we determined that
40 of 235 patients (17.0%) had results that had
not been detected by conventional cytogenetic
analysis.
In a comparison of genetic mutations that
were identified on whole-genome sequencing
with those that were identified on high-coverage
(>500×) targeted clinical sequencing involving
102 patients, we found sensitivities of 84.6% for
single-nucleotide variants and 91.5% for insertion–deletion (indel) mutations, along with a
n engl j med 384;10

positive predictive value of more than 99% for
variants with a minimum variant allele fraction
of 5% (Fig. 2A and Table S6). Similar performance was observed when considering only
mutations in genes necessary for risk stratification in patients with AML, including a combined
sensitivity of 87.5% for single-nucleotide variants
and indels in ASXL1, CEBPA, FLT3, NPM1, RUNX1,
and TP53 (Fig. S2D and S2E). False negatives occurred either because the variants were in subclones or were at low coverage positions on
whole-genome sequencing (Fig. S2F and S2G);
such variants were more readily detected with
higher coverage sequencing (Fig. S2H).20
Clinical Feasibility and Diagnostic Yield

We evaluated the feasibility of using whole-
genome sequencing for routine clinical testing
by prospectively sequencing samples obtained
from 117 consecutive patients (Table S7). For
this cohort, whole-genome sequencing was performed in weekly batches with a median batch
size of 4 (range, 1 to 11) with the use of bone
marrow aspirate samples submitted for karyotyping and FISH studies from April 2019 through
February 2020. The median total processing
time was 5.1 days, which included 2 days for library preparation, 2 days for sequencing, and
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Figure 2. A Comparison of WGS with Conventional Cytogenetic Analysis and Targeted Gene Sequencing.
Panel A shows the sensitivity of WGS for the detection of recurrent structural variants (SVs) and copy-number alterations (CNAs) as
compared with conventional cytogenetic analysis and for the detection of single-nucleotide variants (SNVs) and insertion–deletions
(INDELs) as compared with high-coverage targeted gene sequencing. I bars denote 95% confidence intervals. Panel B shows the identification and confirmation by WGS of 13 new recurrent SVs that were not detected by conventional cytogenetic analysis, as supported by
orthogonal methods, including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) with sequencing of SV breakpoints, or detection of fusion transcripts in RNA-sequence (RNA-seq) data. Panel C shows the identification of 21 new CNAs in 14 patients; 12 of these alterations were confirmed by chromosomal microarray (CMA), FISH, or sequence-defined breakpoints. An additional
9 CNAs were identified by WGS only and could not be confirmed by CMA (in 6 patients) or confirmation was not attempted because of
the size or abundance of the CNA event (in 3 patients). CNAs were also identified in 13 patients with ambiguous or inconclusive results
on cytogenetic analysis. Additional details regarding these comparisons are provided in Tables S4 and S5 and Figure S2C in the Supplementary Appendix.

less than 1 day for analysis (Fig. 3A). The shortest times were about 3 days (approximately 78
hours), when clinical laboratory staffing allowed
samples to be sequenced in dedicated sequencing runs immediately after library generation.
Sequencing was successful in all the samples, and
only 5 samples (4.3%) had less than 25× genome
coverage in a single assay run. Seven samples
required manual review of the automated copynumber alteration calls, with the remaining 110
samples (94.0%) needing no additional interventions to finalize the sequencing report.
This set of consecutive patients was also
evaluated to estimate the diagnostic yield from
whole-genome sequencing as compared with testing with cytogenetic analysis and targeted sequencing. This analysis was performed separately
in samples obtained from patients with AML and
in those obtained from patients with MDS.
(Seven patients with other diagnoses were excluded from this analysis.) In the AML samples,
930

n engl j med 384;10

the comparisons included clinical results from a
standard FISH panel3,21 along with cytogenetic
analysis and targeted sequencing to provide a
realistic estimate of the expected yield of wholegenome sequencing. In this prospective cohort,
results from conventional cytogenetic analysis
and FISH assays in the 68 patients with AML
resulted in the diagnosis of acute promyelocytic
leukemia with the fusion gene PML–RARA in
5 patients and in the assignment of 27 patients
to the adverse-risk group, 10 to the intermediaterisk group, and 19 to the favorable-risk group on
the basis of established guidelines3,8; 7 patients
had unsuccessful or inconclusive results on cytogenetic analysis and could not be assigned to a
risk group (Table S7). Four patients were assigned
to risk groups solely on the basis of positive
FISH results for either PML–RARA (1 patient) or
del(5q) (3 patients) (Fig. 3B).
Whole-genome sequencing that was performed
on samples obtained from the same cohort iden-
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tified new abnormalities that were not present in
the karyotype analysis or reported by FISH in 17
of 68 patients (25%). These abnormalities included cryptic or complex chromosomal rearrangements in 5 patients, new copy-number alterations that resulted in a complex karyotype in
4 patients, and identification of either a normal
karyotype (in 4 patients) or 1 or 2 cytogenetic
abnormalities in patients with inconclusive or
unsuccessful results by cytogenetic analysis (in
4 patients) (Table S8). Using data only from
whole-genome sequencing and a PCR assay for
FLT3-ITD, we reclassified 10 of 68 patients (15%)
without acute promyelocytic leukemia to a risk
group that differed from the one that was based
on conventional testing (Fig. S3A). A similar
yield was observed for the 42 prospective patients with MDS; of these patients, 12 (29%) had
inconclusive results on cytogenetic analysis or
new findings on whole-genome sequencing and
9 (21%) were assigned to a new IPSS-R risk category (Fig. S3B and Tables S7 and S8). These
findings bring the combined number of patients
with a reclassified risk-group assignment to 19
of all 117 patients (16.2%) who were included in
this prospective cohort.
Predictive Value Using Existing Genetic-Risk
Categories

We next asked whether whole-genome sequencing could be used in place of cytogenetic analysis to predict clinical outcomes using existing
genetic risk groups. To avoid the confounding
effect of hematopoietic stem-cell transplantation
on outcome, we focused our analysis on 71 patients with AML who did not undergo this procedure, including 41 prospective and 30 retrospective patients; 58 patients (82%) received
intensive induction chemotherapy, whereas the
remaining 13 were treated with hypomethylating
agents. These patients were assigned to a genetic risk group on the basis of whole-genome
sequencing alone or conventional testing (the
combined results of cytogenetic analysis, clinical
FISH results, and targeted sequencing). The
FLT3-ITD mutational status that was based on a
PCR assay was used in both these classifications.
Risk-group assignments that were based on
conventional testing were in agreement with the
results from whole-genome sequencing for 63 of
71 patients (89%); 8 patients were reassigned to
a different risk category, including 5 who had
new adverse-risk findings that were identified by
n engl j med 384;10

whole-genome sequencing (Table S9 and Fig.
S4A). Risk groups that were defined according
to the two methods had the expected associations with overall survival (adjusted P = 0.09 by
log-rank test in groups identified by conventional testing; adjusted P = 0.01 by log-rank test
in groups identified by whole-genome sequencing) (Fig. 4A and 4B). Whole-genome sequencing
provided slightly better identification of patients
with adverse risk and poor outcomes than conventional testing, with a hazard ratio for death
of 0.32 (95% confidence interval [CI], 0.11 to
0.92) on age-adjusted Cox regression analysis, as
compared with a hazard ratio of 0.66 (95% CI,
0.17 to 1.05) by conventional risk-group analysis.
Similar results were observed in a larger cohort
of 101 patients who were treated with either
consolidation chemotherapy or stem-cell transplantation (Table S9 and Fig. S4B and S4C).
We reasoned that whole-genome sequencing
could have the greatest benefit for patients for
whom cytogenetic results are unavailable at diagnosis, which occurs in up to 20% of patients
with AML.7,22-24 Thus, we used whole-genome sequencing to evaluate 27 patients with AML who
were not treated with stem-cell transplantation
(of whom 22 received standard induction chemotherapy), who could not be assigned to a risk
group at the time of diagnosis because of unsuccessful cytogenetic analysis (in 6 patients), inconclusive results (in 13), or unknown results (in 8),
and who had no reports of risk-defining events
by FISH (Table S10). The mean age at diagnosis
in this cohort was similar to that of patients
with defined cytogenetic risk (60.8 years and
54.7 years, respectively), and the median overall
survival was 11.2 months (95% CI, 5.6 to 38.8)
(Fig. 4C). In this cohort, whole-genome sequencing identified risk-defining chromosomal abnormalities in 4 patients, including KMT2A and
RUNX1–RUNXT1 rearrangements in 1 patient each
or a complex karyotype in 2 patients; the remaining 23 patients had either a normal karyotype or one or two abnormalities and were
assigned to a risk category on the basis of

mutations identified by whole-genome sequencing (Table S10 and Fig. S4D).
Survival analysis of these patients showed
that risk predictions that were based on wholegenome sequencing also correlated with outcomes, with significantly longer overall survival
in 21 patients with intermediate or favorable risk
(median survival, 20.5 months; 95% CI, 5.6 to
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38.8) than in 6 patients with adverse risk (median survival, 3.3 months; 95% CI, 1.7 to 18.9;
adjusted P = 0.03 by log-rank test) (Fig. 4D); hazard ratio of 0.29 (95% CI, 0.09 to 0.94) by ageadjusted Cox regression analysis. This survival
difference was superior to that resulting from
the assignment of patients to risk groups on the
basis of gene mutations alone (Fig. S4E) and was
maintained when 11 additional patients with
inconclusive results on cytogenetic analysis who
underwent allogeneic stem-cell transplantation
932

n engl j med 384;10

were included in this cohort (total of 38 patients)
(Table S10 and Fig. S4F).

Discussion
In this study, we demonstrated the clinical utility of whole-genome sequencing for the genomic
evaluation of patients with AML or MDS. Results
from 263 patients showed that such sequencing
was equivalent to or better than conventional
testing, both in analytical performance and clini-
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Figure 3 (facing page). Clinical Feasibility and Diagnostic
Yield of WGS-Based Genomic Profiling in 117 Consecutive
Patients.
Panel A shows the time it took to process samples obtained from 117 consecutive patients with AML or MDS
by means of WGS from April 2019 through February 2020.
The median processing time for all study patients is indicated by the dashed horizontal black line. The height
of each bar shows the total time in days for processing,
starting from construction of the sequencing library
and ending with completion of the automated final report for an individual patient sample. The duration of
each individual step (as obtained from time stamps recorded in the information management system of the
clinical laboratory) is indicated by the shaded bar segments and includes the duration of library generation
and quality assessment, sequencing, and analysis and
reporting. These times reflect the processing time plus
waiting time before the next step. Longer turnaround
times occurred because of delays between steps, rather
than longer processing times. The dashed horizontal
red lines show the recommended maximum turnaround
time for FISH testing and conventional cytogenetic analysis, according to published recommendations,21 although
shorter turnaround times occur in many laboratories.
Panel B shows the yield of new WGS findings in samples obtained from 68 unselected, consecutive patients
with AML. The top panel shows the cumulative number
of patients with new genomic findings that were identified by WGS, as compared with conventional cytogenetic analysis or FISH, performed at the time of diagnosis, along with the cumulative number of patients
with new events that changed the category of genetic
risk group on the basis of established European Leukemia Network (ELN) guidelines.3 FISH testing included
assays for PML–RARA, CBFB–MYH11, RUNX1–RUNX1T1,
del(5q), and chromosome 7 deletion, according to recommendations3,21; all testing was performed in samples
obtained from 60 of 68 patients (88%), and subgroups
of these assays were performed for the remaining patients. The results of ELN assignments to a genetic risk
group by WGS, conventional cytogenetic analysis with
FISH, and cytogenetic analysis alone are shown in the
middle panel. The red asterisk indicates that the patient’s
risk group was reclassified according to the WGS results,
and the red arrow indicates that the conventional riskgroup assignment was based on FISH results alone.
Genomic events that were detected by WGS are shown
in the bottom panel and are labeled as concordant with
cytogenetic analysis, FISH, or target sequencing (in black),
new findings made by WGS (in blue), and new findings
that resulted in a change in the ELN genetic risk group
(in red). The status regarding internal tandem duplication
in FLT3 (FLT3-ITD) and the allele ratio as determined
by PCR were used for both conventional and WGS-based
risk stratifications.

cal applicability. Whole-genome sequencing detected 100% of the clinically significant abnormalities that had been identified by cytogenetic
analysis and clinical FISH assays. In addition,
n engl j med 384;10

sequencing provided new genetic information in
25% of patients, more than half of whom would
have been assigned to a different genetic risk
category with results from conventional testing.
In practice, the diagnostic yield of whole-genome
sequencing will depend on laboratory-specific
karyotyping practices and the use of FISH or
other ancillary testing; some rapid diagnostic
assays may still be required for urgent treatment
decisions (e.g., FISH or quantitative PCR for
PML–RARA rearrangements and PCR for FLT3-ITD
mutations). However, our study shows that wholegenome sequencing can provide definitive results for clinically relevant genomic events with
the use of a single test. Prospective real-time
sequencing of samples obtained from consecutive patients showed that such sequencing yields
complete genomic information in a clinically relevant timeframe. This speed was made possible
by faster laboratory methods and automated data
analysis that focused on clinically relevant mutations, which allowed us to generate reports in as
little as 3 days. We also found that such results
can be used for risk predictions with existing,
clinically validated risk-stratification systems.
Although larger studies involving more patients
will be required to firmly establish the clinical
performance of whole-genome sequencing, our
proof-of-concept study shows that this method
has the potential to add prognostic value by expanding risk stratification to more patients, especially for those with inconclusive results on cytogenetic analysis, where whole-genome sequencing
could have an immediate effect on treatment
decisions.
We found that the logistical barriers for the
genomic profiling of tumors by whole-genome
sequencing can essentially be eliminated with
the approaches described here. However, an additional (and major) barrier to implementation
has been cost. Unlike other clinical assays in
which technical labor is a substantial expense,
the cost of whole-genome sequencing is driven
nearly entirely by the sequencing itself. As a result, the continued decrease in the price of sequencing25 now makes the costs associated with
this method similar to those of current testing
platforms, which are estimated to range from
$1,000 to $2,000 per patient.26 (Details regarding cost comparisons are provided in the Supplementary Appendix.) The current cost of reagents,
technical labor, and analysis for whole-genome
sequencing with the approach described here is
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Figure 4. Risk Assessment by WGS in Patients with AML, According to Existing Genetic Risk Groups.
Panel A shows overall survival for 71 patients with AML who were treated with chemotherapy alone after remission, as stratified into established ELN genetic risk groups3 on the basis of a combination of conventional cytogenetic analysis, FISH, and targeted gene sequencing. Panel B shows the same cohort as in Panel A with risk stratification according to WGS results. The ratio of the mutated FLT3-ITD allele
to the wild-type allele, as determined by PCR, was used for both the conventional and WGS classifications; the presence or absence of
the mutation was used when allele ratios were not available. Panel C shows the clinical outcomes for 27 patients for whom genetic risk
could not be determined because of inconclusive, unsuccessful, or unknown results on cytogenetic analysis. The median survival in this
cohort was 11.2 months (95% confidence interval [CI], 5.6 to 38.8). Panel D shows the stratification of the cohort in Panel C into established genetic risk groups with the use of WGS results, which predicted shorter overall survival for patients at adverse risk than for those
at intermediate or favorable risk (not adverse) (age-adjusted hazard ratio for death for intermediate or favorable risk versus adverse risk,
0.29; 95% CI, 0.09 to 0.94). All P values were calculated with the use of a log-rank test for equal survival among the groups and were adjusted for multiple comparisons.

approximately $1,900 on the basis of a list price
of approximately $11 to generate 1 billion base
pairs of sequence data. In high-volume laboratories where sequencing costs are lower (approximately $7 per Gbp),25 the cost would be about
$1,300. Although the actual charge for clinical
whole-genome sequencing will probably be high934
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er owing to the additional costs associated with
clinical-laboratory implementation, these calculations suggest that this method is likely to
reach price parity with standard testing when
sequencing falls below $5 per Gbp. Since sequencing data can also provide additional genetic
information that is often obtained by means of
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other genetic assays (e.g., pharmacogenetic testing or HLA typing), price parity for some patients will come even sooner.
Implementing whole-genome sequencing for
clinical testing can provide a unified, stable, and
extensible platform that minimizes laboratoryspecific bias and that can be standardized throughout the world. Although our study focused on
myeloid cancers, many of the advantages of
whole-genome sequencing that we observed will
directly apply to patients with other cancers.
Whole-genome sequencing can be performed on
DNA from tissue biopsy samples of solid tumors,
which are often insufficient for standard molecular assays and difficult to culture for cytogenetic studies. The benefits could be even greater
for these cancer types, in which whole-genome
sequencing could be used to rapidly survey the
entire genome for an expanding number of key
mutations and structural alterations with only a
small amount of DNA. Such an approach would
simplify genomic testing for these patients and
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